To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double blinded, placebo-controlled Phase II study to investigate the
efficacy and safety of ceftriaxone in patients with mild to moderate Parkinson's disease
dementia (PDD).This study will enroll approximately 106 patients to have up to 84 evaluable
subjects, and conduct in Chung Shan Medical University Hospital, National Taiwan University
Hospital,Taichung Veterans General Hospital, Kaohsiung Medical University Hospital and Tungs'
Taichung MetroHarbor Hospital.